DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring pharmaceutical company Adeona Pharmaceuticals Inc. (AMEX:AEN). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/AEN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Adeona Pharmaceuticals Inc. (AEN) is a development-stage, specialty pharmaceutical company that is developing orally active, proprietary, late-stage drug candidates for the treatment of autoimmune and central nervous system diseases. The Company's strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have demonstrated clinical efficacy for the treatment of unmet medical diseases. AEN remains focused on developing treatments for rheumatoid arthritis (RA), multiple sclerosis (MS), dry age-related macular degeneration (AMD) and fibromyalgia.
Message Board Search for AEN: http://www.boardcentral.com/boards/AEN
In the report, the analyst notes:
"The net loss for the quarter ended September 30, 2009 was $626,075 or $0.03 per share. Of this, $325,662 was attributable to research and development expenses and $351,646 was attributable to general and administrative expenses.
"AEN last week announced that the ongoing clinical trial of its Trimesta(TM) (oral estriol) drug candidate being conducted by Dr. Rhonda Voskuhl, director, UCLA Multiple Sclerosis Program, UCLA Dept. of Neurology has received an additional $860,440 in grant funding through the American Recovery and Reinvestment Act. The current phase II/III clinical study is a double-blind, placebo-controlled trial taking place at 16 sites in the U.S. and will enroll up to 150 female Multiple Sclerosis (MS) patients. Investigators will administer Trimesta along with glatimer acetate (Copaxone(R)), an FDA approved therapy for MS, to women between the ages of 18-50 who have been recently diagnosed with relapsing-remitting MS. This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the National MS Society's Southern California chapter, with support from the National Institutes of Health (NIH)."
To read the entire report visit: http://www.stockpreacher.com/n/AEN
See what investors are saying about AEN at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.